Stock DNA
Pharmaceuticals & Biotechnology
CNY 21,253 Million (Large Cap)
21.00
NA
2.60%
-0.70
13.46%
2.32
Revenue and Profits:
Net Sales:
1,170 Million
(Quarterly Results - Sep 2025)
Net Profit:
299 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.06%
0%
-6.06%
6 Months
-30.02%
0%
-30.02%
1 Year
50.41%
0%
50.41%
2 Years
99.31%
0%
99.31%
3 Years
63.1%
0%
63.1%
4 Years
75.33%
0%
75.33%
5 Years
-18.17%
0%
-18.17%
Chengdu Kanghong Pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.05%
EBIT Growth (5y)
13.67%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.67
Sales to Capital Employed (avg)
0.51
Tax Ratio
12.21%
Dividend Payout Ratio
46.33%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.39%
ROE (avg)
9.96%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
2.85
EV to EBIT
15.02
EV to EBITDA
12.69
EV to Capital Employed
6.74
EV to Sales
4.24
PEG Ratio
17.27
Dividend Yield
2.18%
ROCE (Latest)
44.83%
ROE (Latest)
13.70%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
1,170.20
1,254.90
-6.75%
Operating Profit (PBDIT) excl Other Income
339.00
427.80
-20.76%
Interest
0.00
0.00
Exceptional Items
1.20
-0.90
233.33%
Consolidate Net Profit
299.30
325.20
-7.96%
Operating Profit Margin (Excl OI)
289.70%
293.60%
-0.39%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -6.75% vs 4.69% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -7.96% vs -18.00% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
4,417.20
3,901.40
13.22%
Operating Profit (PBDIT) excl Other Income
1,465.20
1,324.60
10.61%
Interest
0.40
0.30
33.33%
Exceptional Items
0.30
-0.80
137.50%
Consolidate Net Profit
1,177.00
1,031.10
14.15%
Operating Profit Margin (Excl OI)
278.80%
281.70%
-0.29%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 13.22% vs 16.21% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 14.15% vs 19.09% in Dec 2023
About Chengdu Kanghong Pharmaceutical Group Co., Ltd. 
Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






